A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial.

J Neuromuscul Dis · 2021 · PMC8543277 · PMID 34120912

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

For the change from baseline in 10 meter walk/run speed, treatment group differences did not reach statistical significance, although there was less decline in the edasalonexent group compared to placebo ( Fig. 3E and F ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.